FDA has proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list. The proposal would materially limit 503B bulk compounding of these GLP-1 products. Comments on the ...
On April 30, 2026, the U.S. Food and Drug Administration announced that it is proposing to exclude semaglutide, tirzepatide, and liraglutide from ...
Incretin class drugs are associated with the most favorable CGM-based outcomes among glucose-lowering medications for type 2 ...
MedPage Today on MSN
FDA Intensifies Crackdown on GLP-1 Compounding
Agency proposal would exclude semaglutide, tirzepatide, and liraglutide from 503B bulks li ...
The US Food and Drug Administration (FDA) yesterday announced it is proposing to exclude semaglutide, tirzepatide and ...
Children who used the weight loss drug liraglutide in a late-stage trial lost significantly more weight than children who got a placebo, according to a new study. Doctors say it can be extremely ...
In a comparison of injectable GLP-1 receptor agonists, semaglutide (Wegovy) appeared to edge out liraglutide (Saxenda) when it came to weight loss, according to the phase IIIb STEP 8 study. In a ...
An old GLP-1 that has since been outshined by Ozempic may have a new path to the limelight. In a small phase 2 trial of patients with mild Alzheimer’s disease, Novo Nordisk’s liraglutide slashed ...
Talk about a leg up. Researchers say that taking a popular obesity medication and exercising regularly can lead to weight loss — and bone health is still maintained. Bone loss typically accompanies ...
In Canada, health regulators took one step to fill that gap by approving a generic version of semaglutide, which is the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results